UCB (LTS:0NZT) Accumulated Depreciation : €-1,388 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is UCB Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

UCB's quarterly accumulated depreciation declined from Dec. 2022 (€-1,273 Mil) to Jun. 2023 (€0 Mil) but then increased from Jun. 2023 (€0 Mil) to Dec. 2023 (€-1,388 Mil).

UCB's annual accumulated depreciation increased from Dec. 2021 (€-1,145 Mil) to Dec. 2022 (€-1,273 Mil) and increased from Dec. 2022 (€-1,273 Mil) to Dec. 2023 (€-1,388 Mil).

UCB Accumulated Depreciation Historical Data

The historical data trend for UCB's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Accumulated Depreciation Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-940.00

-1,026.00

-1,145.00

-1,273.00

-1,388.00

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accumulated Depreciation	Get a 7-Day Free Trial															-1,145.00	-	-1,273.00	-	-1,388.00

UCB Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

UCB Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of UCB's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (LTS:0NZT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (LTS:0NZT) Headlines

No Headlines